AzTrials
AzTrials

HelminthiasisNCT00367627

Relative Efficacy of Two Regimens of Ante-helminthic Treatment

A study testing Albendazole in people with Helminthiasis, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The most common soil transmitted helminthic infections(STHI) includes infection with Ascaris lumbricoides, Trichuris trichiura, and Hookworm. Growth retardation, malnutrition, anemia, impaired cognitive function and immunosuppression are main manifestations in children. Read more about this study

Who is it for?
Ages 2 to 5 years
Conditions the study is for
Helminthiasis
What is being tested?
Albendazole
How many people
200 participants
Where
1 siteBangladesh
Study dates
Dec 2006to May 2008
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 2 to 5 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • age of the child is 2-5 years old,
  • he/she has not been suffering from serious chronic illness,
  • the child stool test must be positive for STH,
  • he/she had not been taken any antehelminthic drug in the previous six months,
  • parents/guardian are agree for their child participation in the study. e -

Who cannot join

  • age of the child less than 2 years old and more than 5 years old,
  • his/her stool test negative for any intestinal helminth,
  • he/she has been suffering from serious chronic illness,
  • parents/guardian are not willing to give consent for their child's participation in the study,
  • if he/she receives any antehelminthic drug after survey but before the study interventions.

Trial locations and contacts

1 site in 1 country.

Bangladesh1 site
  • ICDDR,B: Centre for Health and Population Research

    Dhaka, 1212

Other trials in Bangladesh

About this study

The most common soil transmitted helminthic infections(STHI) includes infection with Ascaris lumbricoides, Trichuris trichiura, and Hookworm. Growth retardation, malnutrition, anemia, impaired cognitive function and immunosuppression are main manifestations in children. Even within the developing world, wide differences exist in prevalence rates. The poorest countries have higher levels of STHI than those with a lower incidence of poverty. According to an estimate made by the WHO, the prevalence of A. lumbricoides, T. trichiura and Hookworm in South Asia was 27%, 20% and 16% respectively. Given that the prevalence of STHI in urban slums in Bangladesh is much higher than the other parts of the world and Asia and that there are major health and socio-economic consequences of such infections, it is important that we come up with effective means of reducing the prevalence of such infections. 60-80% of preschool children in urban slums of Bangladesh are infected with these STHI due to poor hygiene . At present deworming at six months interval is recommended but the effectiveness of this regimen of dewormig is questionable.

  1. Hypothesis: Ante-helminthic treatment at every three month is more effective than ante-helminthic treatment at every six months to reduce soil transmitted helminthic infection, to reduce diarrheal and respiratory illness to improve nutritional status in preschool children.
Read more

3.Objective: The main objectives of the proposed study is to compare the relative efficacy of two different ante-helminthic treatment regimens to reduce the prevalence of STHI, diarrheal diseases, respiratory illness and to improve nutritional status in children 4. Design: The population of the study will be preschool children aged 2-5 year and will be selected randomly from an urban of Dhaka. They will be divided into two groups randomly. One group will get ante-helminthic at every three months interval and the other groups will get at six months interval for one year. Stool samples will be collected at the baseline and after three months completing one-year treatment of the above mentioned regimen. Blood haemoglobulin and nutritional status will also be measured at baseline and after three months of completion of treatment as mentioned above. The treatment will be 400 mg of Albendazole in a single dose.

  1. Potential Impact: The findings of the research can be implemented by the government and non-government organization.
Read the detailed description

Study design and population:

The study population will be the children aged 2-5 years old in the study area. All children aged 2-5 years old in one slums of the study area will be listed and will be invited to participate in the study.

Parents will be explained the purpose of the study and will be asked for written consent for participation of their children in the study. If the parents give the consent then a stool pot will be given to them to collect stool samples for microscopic examination for intestinal parasites. The inclusion criteria are; 1) age of the child is 2-5 years old, 2) he/she has not been suffering from serious chronic illness, 3) the child stool test must be positive for STH, 4) he/she had not been taken any antehelminthic drug in the previous six months, 5) parents/guardian are agree for their child participation in the study. The exclusion criteria are; 1) age of the child less than 2 years old and more than 5 years old, 2) his/her stool test negative for any intestinal helminth, 3) he/she has been suffering from serious chronic illness, 4) parents/guardian are not willing to give consent for their child's participation in the study, 5) if he/she receives any antehelminthic drug after survey but before the study interventions. The survey will be done in the first months of the study, and then children will be enrolled according to above mentioned inclusion/exclusion criteria. During screening if any child is found severely malnourished it will be considered as'danger sign' according to WHO and IMCI guideline he/she will be referred to an appropriate facility even if she/he is not enrolled in the study. Simple randomization technique will be applied to divide the children into two groups: A) Conventional treatment group who will receive anti-helminthic treatment 400 mg of Albendazole in a single dose at six month interval and B) Intervention group, who will receive anti-helminthic 400 mg of Albendazole in a single dose treatment at three months interval. Stool samples will be collected from both groups prior to anti-helminthic therapy and will be examined quantitatively. However stool examination will not be carried out for intestinal parasite after giving 400 mg of Albendazole at 12 months.

Sample size calculation:

Sample size has been calculated using different predicted values of different out come variables and is shown in the Table 1. A sample size of 200 children, 100 in each group will be sufficient for the study.

Table 1. Sample size calculation table Indicator Conventional treatment group Intervention treatment group Power of the study 95% CI SD* Number in each group Total number adjusted for 10% drop out Cure rate 40% 65% 90% 95% - 78 170 HAZ < -2 38% 19% 90% 95% - 84 184 Incidence of E. histolytica infection per 100 child-year 20a 15 90% 95% 10 85 188 Average diarrheal episode per child 2a 1 90% 95% 1.5 48 106 Mean haemoglobin mg% 10a 12 90% 95% 4 85 188 Respiratory tract infection episode/child 6a 4 90% 95% 3 48 106 * SD = Within group standard deviation

a= Data from our ongoing cohort study in Mirpur

Methods:

Anthropometric measurement: Field Research Assistant will be trained to take weight and height measurement of the children. Anthropometric measurements will be taken by trained FRA at the time of enrollment and then every 3-months. Each child will be weighed in light clothes with an electronic weighing scale. Inter-observer variation up to 2.5% will be allowed. The standing heights of children will be measured to the nearest 0.1 cm using a locally constructed height stick. Again inter-observer variation up to 2.5% will be allowed. Nutritional status will be assessed by comparing the weight and height of the study children with those of NCHS reference population of the same age and sex with the help of Epi6 computer package program and weight for age "Z" score (WAZ) and height for age "Z" score (HAZ) will be computed (29). Malnourished and stunted will be defined by the WAZ score and HAZ score <-2 respectively.

Other disease morbidity: Each study subject will be visited by a community health worker every week and will collect information by asking parents/guardian according to structured questionnaires about diarrheal disease, fever, cough etc. of the child retrospectively for previous seven days. They will work 6 days weekly and every one of them has to visit about 17 households per day for morbidity data collection. Parents/guardian will be advised to seek health care from study physician in study field office in case of any illness of the study child. The study physician will take history and will carry out physical examination and will give treatment to the sick child. If the child does not respond to the given treatment or if his/her condition deteriorates or if the child is seriously ill initially then he/she will be referred to the appropriate referral facilities for treatment, and treatment cost will not be carried out by the project. Asymptomatic E. histolytica infections will not be treated. But symptomatic E. histolytica infections will be treated according to the ICDDR, B Dhaka Hospital treatment guidelines

Intestinal helminth infections induce Th-2 immune response (27), which might favor others viral, bacterial and protozoan infections. De-worming has been shown to improve antibody response (28). In our ongoing cohort study in Mirpur it has been found that children with heavy Trichuris trichiura (TT) infections suffered significantly more from E. histolytica associated infection (un published data) compare to those children with light infection with TT. Based on these observations it can be hypothesized that a frequent de-worming regimen will be associated with less other disease morbidtity like diarrheal diseases, respiratory infections and intestinal protozoan infections with E. histolytica Clinical definitions Diarrhea was defined as having three or more unformed stools in a 24 hour period. A "diarrheal episode" was defined as being separated from another episode by at least 3 diarrhea-free days.

Respiratory tract infection defined as a 'Perceptions of a child who has a cough, is breathing faster than usual with short, quick breaths or is having difficulty breathing, excluding children that had only a blocked nose. (30). No attempt will be done to identify the etiology of the respiratory infection.

Cure rate of STH infection (CR): Cure rate from STH infection is defined as follows:

  • Prevalence before at enrollment - % prevalence at the end of the study CR = --------------------------------------------------------------------------------------------- x 100%
  • Prevalence before at enrollment

Laboratory methods:

Blood hemoglobin measurement: Study physician will measure blood hemoglobin of the child at enrollment and at the end of the study period by hemocytometer at field site. (31).

Stool parasite examination: The community health workers will collect stool samples for qualitative and quantitative intestinal parasite measurement at every three months interval. The stool will be examined by conventional microscopy for qualitative measurement and for quantitative measurement of intestinal helminthes by Kato-Katz or Formalin-ether concentration technique will be used. (32).E. histolytica will be detected by stool microscopy and ELISA as described by R Haque el at(33).

Conditions
Helminthiasis
Being tested
Albendazole
Keywords
Children, Malnutrition, Ascaris Lumbricoides, Trichuris trichiura Morbidity, Helminthiasis, Children 2-5 years, Stool RME +ve for helminthiasis
Medical subject headings
Helminthiasis, Malnutrition

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AlbendazoleDrug

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. To determine the relative efficacy of de-worming at every three months vs. every six month single dose of Albendazole treatment.

Secondary outcomes (1)
  1. To compare additional morbidity information such as diarrheal diseases, respiratory tract infections, nutritional status and E. histolytica associated morbidity between two groups.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Aug 2006 (estimated)
  2. Study startDec 2006
  3. Primary completionMay 2008
  4. Study completionMay 2008

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00367627
Sponsor's protocol ID
2006-026
Status last verified
Aug 2006
First submitted
22 Aug 2006
Last updated
12 Jul 2011
Results posted
No

Questions about this trial

What is this clinical trial studying?

A study testing Albendazole in people with Helminthiasis, run by International Centre for Diarrhoeal Disease Research, Bangladesh at 1 site in Bangladesh.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jul 2011. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Bangladesh. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

To determine the relative efficacy of de-worming at every three months vs. every six month single dose of Albendazole treatment.. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2011.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in